首頁 > 市場調查報告書 > 製藥

神經疾病

市場調查報告書

商品編碼

1911631

神經退化性疾病市場規模、佔有率和成長分析（按藥物類別、疾病適應症、給藥途徑、最終用戶和地區分類）－2026-2033年產業預測

Neurodegenerative Disease Market Size, Share, and Growth Analysis, By Drug Class, By Disease Indication, By Route of Administration, By End User, By Region - Industry Forecast 2026-2033

出版日期: 2025年12月29日 | 出版商:

SkyQuest | 英文 178 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

預計到 2024 年，全球神經退化性疾病市場規模將達到 563.9 億美元，到 2025 年將成長至 604.5 億美元，到 2033 年將成長至 1054.2 億美元，在預測期（2026-2033 年）內複合成長率為 7.2%。

全球神經退化性疾病市場正經歷強勁成長，這主要得益於診斷和治療技術的進步、政府投入的增加以及患者群體結構的變化。針對阿茲海默症、帕金森氏症和肌萎縮性側索硬化症（ALS）等疾病的創新醫療基礎設施建設，凸顯了全球致力於攻克這些疾病的決心。該行業的關鍵發展在於提高治療效果和診斷準確性，包括將人工智慧和機器學習技術應用於腦部掃描分析和個人化治療。此外，5G醫療平台的出現實現了遠端患者監護，並加強了與神經科的溝通，從而加快了決策速度。同時，永續性措施正在推動節能型診斷工具的研發，從而提高農村地區的醫療服務可近性，並促進患者的持續管理。

全球神經退化性疾病市場促進因素

正子斷層掃描（PET）、基於生物標記的血液檢測以及人工智慧驅動的神經影像等診斷技術的進步，顯著提高了神經退化性疾病的早期準確識別率。這些進步有助於透過及時檢測改善患者管理和治療效果。因此，神經退化性疾病市場在診斷、治療和監測等各個領域都經歷了顯著成長。這些創新不僅推動了對更有效解決方案的需求，也刺激了對臨床試驗和研究舉措的投資增加，從而進一步促進了全球神經退化性疾病市場的擴張。

限制全球神經退化性疾病市場的因素

全球神經退化性疾病市場面臨許多限制因素，其中最主要的是先進療法的高成本。這些療法通常涉及昂貴的藥物、持續的護理以及專業的診斷程序，其費用之高昂令人望而卻步，尤其是在中低收入國家，這成為治療的一大障礙。高額的自付費用阻礙了基因療法和單株抗體等創新療法的普及和廣泛應用。這種限制不僅影響了這些最先進治療的市場滲透率，也延誤了早期療育，最終影響到各個地區患者的長期治療效果。因此，消除這些經濟障礙對於改善神經退化性疾病領域關鍵療法的可近性至關重要。

全球神經退化性疾病市場趨勢

隨著人工智慧 (AI) 融入診斷流程，全球神經退化性疾病市場正經歷重大變革。這項技術進步利用 AI 演算法，透過分析患者病歷、血液生物標記和腦部影像，在臨床症狀出現之前識別出阿茲海默症疾病，從而提高了早期檢測率。因此，這項創新不僅縮短了診斷時間，也提高了臨床準確性，重塑了市場動態。醫療機構對 AI 工具的日益普及是一大趨勢，使 AI 成為神經診斷技術的前沿技術，並影響該領域的治療模式。

北美洲
- 美國
- 加拿大
歐洲
- 德國
- 西班牙
- 法國
- 英國
- 義大利
- 其他歐洲地區
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 亞太其他地區
拉丁美洲
- 巴西
- 其他拉丁美洲地區
中東和非洲
- 海灣合作理事會國家
- 南非
- 其他中東和非洲地區

競爭資訊

前五大公司對比
主要企業的市場定位（2025 年）
主要市場參與者所採取的策略
近期市場趨勢
公司市佔率分析（2025 年）
主要企業公司簡介
- 公司詳情
- 產品系列分析
- 依業務板塊進行公司股票分析
- 2023-2025年營收年比比較

主要企業簡介

Biogen
Pfizer, Inc.
Hoffmann-La Roche Ltd
Merck & Co., Inc.
Novartis AG
Teva Pharmaceutical Industries Ltd.
Orion Pharma
UCB SA
ACADIA Pharmaceuticals Inc.
Lundbeck A/S

結論與建議

簡介目錄

Product Code: SQMIG35I2404

Global Neurodegenerative Disease Market size was valued at USD 56.39 Billion in 2024 and is poised to grow from USD 60.45 Billion in 2025 to USD 105.42 Billion by 2033, growing at a CAGR of 7.2% during the forecast period (2026-2033).

The global neurodegenerative disease market is experiencing robust growth driven by advancements in diagnostic and treatment technologies, increased government funding, and evolving patient demographics. Innovative healthcare infrastructures are being established, focusing on diseases like Alzheimer's, Parkinson's, and ALS, highlighting the global commitment to addressing these conditions. Significant developments in the industry have enhanced treatment efficacy and diagnostic accuracy, with the integration of AI and machine learning for analyzing brain scans and personalizing therapy. Additionally, the emergence of 5G-enabled medical platforms allows for real-time remote patient monitoring and improved communication with neurologists, facilitating quicker decision-making. Furthermore, the push for sustainability is spurring the creation of energy-efficient diagnostic tools, enhancing accessibility in rural areas while supporting ongoing patient management.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Neurodegenerative Disease market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Neurodegenerative Disease Market Segments Analysis

Global Neurodegenerative Disease Market is segmented by Drug Class, Disease Indication, Route of Administration, End User and region. Based on Drug Class, the market is segmented into Immunomodulator, Interferons, Decarboxylase Inhibitors, Dopamine Agonists and Others. Based on Disease Indication, the market is segmented into Multiple Sclerosis, Parkinson's Disease, Alzheimer's Disease, Spinal Muscular Atrophy (SMA) and Others. Based on Route of Administration, the market is segmented into Oral, Injection and Transdermal. Based on End User, the market is segmented into Hospital Pharmacy, Retail Pharmacy and Online Pharmacy. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Neurodegenerative Disease Market

Advancements in diagnostic technologies such as PET scans, biomarker-based blood tests, and AI-driven neuroimaging have greatly enhanced the early and accurate identification of neurodegenerative diseases. This progress facilitates improved patient management and treatment outcomes through timely detection. Consequently, the market for neurodegenerative diseases is witnessing significant growth across various segments, including diagnostics, therapeutics, and monitoring. These innovations are not only driving the demand for more effective solutions but also encouraging increased investment in clinical trials and research initiatives, further propelling the expansion of the global neurodegenerative disease market.

Restraints in the Global Neurodegenerative Disease Market

The Global Neurodegenerative Disease market faces considerable constraints due to the high costs associated with advanced therapies. These treatments often involve expensive medications, continuous care, and specialized diagnostic procedures, which can be prohibitively expensive, especially in low- and middle-income countries. The substantial out-of-pocket expenses hinder the availability and adoption of innovative approaches such as gene therapy and monoclonal antibodies. This limitation not only impacts the market penetration of these cutting-edge treatments but also delays early intervention, ultimately affecting long-term patient outcomes across different regions. Addressing these financial barriers is crucial for improving access to vital therapies in the neurodegenerative disease sector.

Market Trends of the Global Neurodegenerative Disease Market

The global neurodegenerative disease market is experiencing a significant transformation driven by the integration of artificial intelligence (AI) into diagnostic processes. This technological advancement allows for enhanced early detection by leveraging AI algorithms to analyze patient histories, blood biomarkers, and brain imaging, facilitating the identification of conditions such as Alzheimer's disease before clinical symptoms manifest. Consequently, this innovation not only accelerates diagnosis times but also increases clinical accuracy, reshaping market dynamics. The growing adoption of AI tools among healthcare providers stands out as a key trend, positioning AI at the forefront of neurodiagnostic advancements and influencing treatment paradigms in the sector.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2025
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis
Case Studies
Customer Buying Behavior Analysis

Global Neurodegenerative Disease Market Size by Drug Class & CAGR (2026-2033)

Market Overview
Immunomodulator
Interferons
Decarboxylase Inhibitors
Dopamine Agonists
Others

Global Neurodegenerative Disease Market Size by Disease Indication & CAGR (2026-2033)

Market Overview
Multiple Sclerosis
Parkinson's Disease
Alzheimer's Disease
Spinal Muscular Atrophy (SMA)
Others

Global Neurodegenerative Disease Market Size by Route of Administration & CAGR (2026-2033)

Market Overview
Oral
Injection
Transdermal

Global Neurodegenerative Disease Market Size by End User & CAGR (2026-2033)

Market Overview
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy

Global Neurodegenerative Disease Market Size & CAGR (2026-2033)

North America (Drug Class, Disease Indication, Route of Administration, End User)
- US
- Canada
Europe (Drug Class, Disease Indication, Route of Administration, End User)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Drug Class, Disease Indication, Route of Administration, End User)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Drug Class, Disease Indication, Route of Administration, End User)
- Brazil
- Rest of Latin America
Middle East & Africa (Drug Class, Disease Indication, Route of Administration, End User)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2025
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2025
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

Biogen
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pfizer, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Hoffmann-La Roche Ltd
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck & Co., Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novartis AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Teva Pharmaceutical Industries Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Orion Pharma
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
UCB S.A
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
ACADIA Pharmaceuticals Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Lundbeck A/S
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments